SUMMARY The haemodynamic effects of oral and intravenous salbutamol were investigated in 22 patients with chronic heart failure. Intravenous salbutamol (13 ,tg/min) increased cardiac index by 53 per cent from 1. There was a small rise in heart rate and a variable and not significant change in pulmonary artery enddiastolic pressure. Experiments on isolated rabbit papillary muscle showed that salbutamol, at the concentration which exists in patients, had no detectable positive inotropic effect. It is probable that the increase in cardiac output in patients is primarily the result of reduced afterload caused by vasodilatation. Salbutamol is a useful drug in the treatment of chronic heart failure.
resistance by 28 per cent from 29-4±3-9 units to 21 2±t2-5 units. Heart rate rose by 10 per cent from 101 ±35 beats per minute to 111I±32 beats per minute and pulmonary artery end-diastolic pressure fell by 13 per cent from 26-3 ± 1-8 mmHg to 22-8 ± 21 mmHg. Similar results were obtained after oral salbutamol (8 mg). Cardiac index rose by 40 per cent and systemic vascular resistance fell by 30 per cent. There was a small rise in heart rate and a variable and not significant change in pulmonary artery enddiastolic pressure. Experiments on isolated rabbit papillary muscle showed that salbutamol, at the concentration which exists in patients, had no detectable positive inotropic effect. It is probable that the increase in cardiac output in patients is primarily the result of reduced afterload caused by vasodilatation. Salbutamol is a useful drug in the treatment of chronic heart failure.
Vasodilator drugs are widely advocated in the treatment of both acute and chronic heart failure. '-3 Salbutamol is a relatively specific beta-2 adrenergic agonist which relaxes smooth muscle and reduces systemic vascular resistance.4 The haemodynamic effects of intravenous salbutamol have been studied in normal persons,5 in patients with respiratory disease,6 in patients after acute myocardial infarction,7 in patients with mitral valve disease,8 and in patients after cardiac surgery. In group A patients, measurements were made at rest and after administration of 8 mg oral salbutamol, at half-hourly intervals for two hours and subsequently at one-or two-hourly intervals for a maximum of seven hours. In six patients two sets of control measurements were made one hour apart. Only small and insignificant changes were observed.
In group B measurements were made under control conditions and 40 minutes after the start of an infusion of salbutamol at a dose of 13 Fg/min.
Experiments were undertaken on isolated right ventricular papillary muscles of rabbits (2 to 4 kg). The experimental preparation has been previously described.13 Temperature was 37°C and the stimulation rate 60 beats per minute. The muscles were stretched until developed tension was maximal. Developed tension and the first differential of developed tension (dT/dt) were recorded.
Results

GROUP A: ORAL SALBUTAMOL
The changes in cardiac index over the period of the study are shown in Fig. 1 . There was a rise in all patients with a peak at an average time of 90 minutes. Cardiac index subsequently fell slowly but did not reach control levels within seven hours.
The changes in cardiac index, heart rate, pulmonary artery end-diastolic pressure, systemic arterial mean pressure, systemic vascular resistance, and stroke volume index at the time of maximum cardiac index are shown in Fig. 2 . Cardiac index rose from 2-0 ±0-16 I/min per m2 to 2-8 ±0-27 1/min per m2 after salbutamol (40%, p <0001). Heart rate increased from 83 ±3 to 89 ±4 beats per minute (7%, p < 0 05). Pulmonary artery end-diastolic pressure fell in six patients, but for the whole group there was no significant change. There was no significant change in mean blood pressure which was 86 ±1 8 mmHg before and 82 ±2-7 mmHg after salbutamol. Calculated systemic vascular resistance fell from 24-9 ±2-8 units before to 17-4 ± 2-2 units after salbutamol (30%, p < 0-001). Stroke volume index increased from 25-6 ±2-6 to 31-8 ±3'0 ml/m2 (28%, p < 0-001).
One patient in group A had an episode of angina associated with tachycardia two hours after salbutamol. This patient was treated with sublingual glyceryl trinitrate and the study was discontinued. No other side effects were observed. (37%, p<0-001).
In one patient the infusion of salbutamol had to be discontinued because of the appearance of multiple ventricular ectopic beats. There were no other observed side effects in the patients in group B.
Of the patients in group A, two died from deterioration of heart failure within four weeks of the initial study, and one died at the time of coronary artery bypass operation six weeks after the study. and Goodwin'2 in patients with cardiomyopathy ,ith increasing and some degree of cardiac failure. It appears that Ile experiment in patients with heart failure the effect of salbutamol -ctable change on heart rate is small. dose-response Several differences were apparant under control a significant conditions between the groups of patients given at concentra-oral and intravenous salbutamol. The group given nilar changes intravenous salbutamol had more severe heart differential of failure, were more limited by symptoms, had a lower cardiac index (p <0 05) and stroke volume index (p < 0-001), and had a higher heart rate (p <0-01). Both groups of patients responded to salbutamol in a similar manner, in that cardiac have similar index increased and systemic vascular resistance fell with chronic ( Fig. 2 and 3 ) but in the group given intravenous cardiac index salbutamol there was a rise in blood pressure and a stance with a fall in pulmonary end-diastolic pressure, which riable or small were not seen in the group given oral salbutamol. pressure. The These differences might be attributable to the ex (53%) and different routes of administration of the drug but nce (30%) in are more probably a reflection of the more severe Lol are similar heart failure in the group given intravenous patients after salbutamol. The pulmonary artery end-diastolic iomyopathy,12 pressure in the group given oral salbutamol fell in id not find the the five patients with the highest initial pressures; Wilson et al.11 the failure of the group as a whole to show a sigaller change in nificant fall is partly the result of the inclusion of ed by Sharma patients whose control pulmonary artery enddiastolic pressures were low as a result of treatment with powerful diuretics. In these patients the Sal butamol pulmonary artery end-diastolic pressure presumably (mg/l) increases on the mildest exertion since breathlessness was the predominant symptom. Even in the group given intravenous salbutamol the fall in pulmonary artery end-diastolic pressure, though statistically significant, was small (3 5 mmHg).
The haemodyanamic effects of salbutamol could be the consequence of vasodilatation or the result of a positive inotropic effect. The former is more probable since salbutamol is known to be a beta-2 agonist4 with beta-i activity only at high concentrations. The problem cannot be resolved in vivo because of the difficulties in distinguishing between an increase in cardiac output resulting from a fall in systemic vascular resistance and an increase in cardiac output resulting from increased contractility with reflex vasodilatation. Our results show clearly that oral and intravenous salbutamol increase cardiac output. The fall in pulmonary artery end-diastolic pressure was small and a drug with a greater venodilator effect may be indicated in patients with heart failure and a high pulmonary artery end-diastolic pressure at rest. Though we have used salbutamol orally (4 mg q.d.s.) for periods greater than two months in 10 patients with se.vere chronic heart failure, we have no objective evidence of improvement. Nevertheless, our clinical impression is that in these patients symptomatic benefit is appreciable and side effects rare. A beneficial effect is by no means invariable and we have found no simple method of selecting those who will improve. Salbutamol can also be useful in the treatment of patients confined to bed in hospital with heart failure and oedema unresponsive to large doses of diuretics and digoxin. Intravenous salbutamol was given to such patients for periods of three to 20 days. This treatment enabled patients who previously were languishing in hospital beds to return home. We wish to thank Glaxo Group Research Ltd. and Allen & Hanbury Ltd. for their assistance.
